NOVN

Novartis to buy France's CellforCure to boost cell, gene therapy

ZURICH, Dec 20 () - Novartis is to buy French contract manufacturer CellforCure from biologics company LFB to boost the Swiss drugmaker's capacity to produce cell and gene therapies such as its $475,000 Kymriah cancer treatment.

Novartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure's facilities to a similar factory in Morris Plains, New Jersey, as well as one under construction in Switzerland. Terms of the cash deal were not given.

OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

ZURICH, Dec 20 () - Novartis is to buy French contract manufacturer CellforCure from biologics company LFB to boost the Swiss drugmaker's capacity to produce cell and gene therapies such as its $475,000 Kymriah cancer treatment.

Novartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure's facilities to a similar factory in Morris Plains, New Jersey, as well as one under construction in Switzerland. Terms of the cash deal were not given.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.